Assertio Holdings, Inc. (ASRT)

Market Cap	64.63M
Revenue (ttm)	119.00M
Net Income (ttm)	-30.61M
Shares Out	95.78M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	13.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,339
Open	0.6486
Previous Close	0.6418
Day's Range	0.6486 - 0.6798
52-Week Range	0.5137 - 1.7980
Beta	0.30
Analysts	Strong Buy
Price Target	3.25 (+381.62%)
Earnings Date	Aug 6, 2025

About ASRT

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older;...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 5, 1997
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: ASRT
• Website: https://www.assertiotx.com

Financial Performance

In 2024, Assertio Holdings's revenue was $124.96 million, a decrease of -17.83% compared to the previous year's $152.07 million. Losses were -$21.58 million, -93.50% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for ASRT stock is "Strong Buy." The 12-month stock price target is $3.25, which is an increase of 381.62% from the latest price.

Price Target

$3.25

(381.62% upside)

Analyst Consensus: Strong Buy